Update on Lupuzor’s Pivotal Phase III Study – 11 US Sites Now Open, 5 European Countries Now Recruiting

14th September 2016 - 2:00 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to provide a further update on the progress of its Phase III clinical trial of Lupuzor™, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

Key Trial Highlights

  • Total 11 sites now active in US
  • 5 European countries now recruiting Lupus patients in Czech Republic, France, Germany, Hungary and Poland
  • The final 2 European countries, UK and Italy, to open within the next few weeks
  • Mauritius site already confirmed that over 10 Lupus patients have been pre-screened prior to dosing
Further updates on the progression of the Lupuzor™ Phase III trial will be announced, as appropriate, as the trial progresses. Trial progress can also be viewed at: www.ClinicalTrials.gov/lupuzor

Commenting on the announcement, Tim McCarthy, Chairman, said: “We are delighted by the continued progress of the Lupuzor™ Phase III trial both with the US now having the full 11 sites active and the opening of further countries across Europe. Additionally, we are encouraged following the announcement last week of the opening of a new site in Mauritius, that we have already commenced screening a number of Lupus patients in advance of first dosing. The key milestone this year remains for the completion of the recruitment of the 200 Lupus patients into the trial and we look forward to providing further positive updates on this Lupuzor™ Phase III study as it progresses throughout this year and 2017.”

Share this article